analysis of statistics

Amyris Inc (NASDAQ:AMRS)’s share price plunged -0.55% or -0.03 to reach at $5.45 during previous trading session. A total of 6.23 Million shares exchanged hands, whereas the company’s average trading volume stands at 2.5 Million shares. Amyris Inc (NASDAQ:AMRS) has a market capitalization of $409.19 Million and most recently 75.08 Million outstanding shares have been calculated.

According to sentiments of 2 analysts the mean estimates of short term price target for the company’s stock is marked at $9.5. The most optimistic analyst sees the stock reaching $11 while the most conventional predicts the target price at $8.

In terms of Buy/Sell recommendations, 2 analysts have a consensus rating of 1 on the shares of Amyris Inc (NASDAQ:AMRS). Out of rating recommendations 0 have given the stock a Buy while 2 recommend the stock as Outperform. 0 have given the stock a Hold rating, 0 as Underperform and 0 as Sell.

Amyris Inc (NASDAQ:AMRS)’s shares climbed 60.77% in the past week and soared 35.91% in the last 4 weeks, historically the stock illustrate that its six months performance stands at -24.62% while its year to date performance is at 63.17%.

While taking a glance at financials, we can look at a number of key indicators. Amyris Inc (NASDAQ:AMRS) has a Return on Assets (ROA) of -127. The company currently has a Return on Equity (ROE) of 68 and a Return on Investment (ROI) of 10.4. Average true range (ATR-14) of the company sets at 0.5, along with its weekly and monthly volatility of 17.51% and 10.08% respectively. Relative strength index (RSI-14) for Amyris Inc (NASDAQ:AMRS) is at 72.44. Beta value of the stock stands at 0.28.

The company’s price to free cash flow for trailing twelve months is 0. Its quick ratio for most recent quarter is 0.4 along with current ratio for most recent quarter of 0.4. Total debt to equity ratio of Amyris Inc (NASDAQ:AMRS) for most recent quarter is 0 whereas long term debt to equity ratio for most recent quarter is 0.

Shares of Aveo Pharmaceuticals (NASDAQ:AVEO) plunged -5.21% or -0.03 to reach at $0.59 during previous trading session. Aveo Pharmaceuticals (NASDAQ:AVEO) has a market capitalization of $70.67 Million and most recently 119.78 Million outstanding shares have been calculated. A total of 5.16 Million shares exchanged hands, whereas the company’s average trading volume stands at 2.66 Million shares.

According to 4 analysts Aveo Pharmaceuticals (NASDAQ:AVEO)’s price will reach at $5.5 during 52 weeks. Stock’s minimum price target estimates has been figured out at $3 while the maximum price target forecast is established at $9.

According to the recommendations from 4 analysts stock has mean rating of 2 on the shares of Aveo Pharmaceuticals (NASDAQ:AVEO). Out of rating recommendations 1 have given the stock a Buy while 1 recommend the stock as Outperform. 2 have given the stock a Hold rating, 0 as Underperform and 0 as Sell.

Shares of Aveo Pharmaceuticals (NASDAQ:AVEO) slipped -15.64% in the past week and plunged -71.5% in the last 4 weeks, historically the stock illustrate that its six months performance stands at -72.56% while its year to date performance is at -63.13%.

Total debt to equity ratio of Aveo Pharmaceuticals (NASDAQ:AVEO) for most recent quarter is 0 whereas long term debt to equity ratio for most recent quarter is 0. The company’s price to free cash flow for trailing twelve months is 0. Its quick ratio for most recent quarter is 1.1 along with current ratio for most recent quarter of 1.1.

Average true range (ATR-14) of the company sets at 0.16, along with its weekly and monthly volatility of 15.25% and 11.32% respectively. Relative strength index (RSI-14) for Aveo Pharmaceuticals (NASDAQ:AVEO) is at 19.15. Beta value of the stock stands at 2.06. Aveo Pharmaceuticals (NASDAQ:AVEO) has a Return on Assets (ROA) of -69.9. The company currently has a Return on Equity (ROE) of 48.1 and a Return on Investment (ROI) of 129.7.